Join Toby Batten, Statistics Manager at Veramed and our special guest co-host, Carlo Lanza, as they discuss the evolution, challenges and road ahead of Clinical Oncology – focusing on Phase I, II and III specifically. Carlo and Toby will share how to think outside the box from a clinical and statistical point of view, address common pitfalls, improve study design, and more.
Agenda
- What’s new and how does it change our interpretation of dose-toxicity data
- Designing early phase oncology studies: thinking outside the box
- Considerations when selecting the recommended phase II dose and assessing early efficacy data
- Looking to the future: Planning beyond early phase
